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OBJECTIVES Using recent data, we sought to identify risk factors associated with in-hospital mortality
among patients undergoing percutaneous coronary interventions.
BACKGROUND The ability to accurately predict the risk of an adverse outcome is important in clinical
decision making and for risk adjustment when assessing quality of care. Most clinical
prediction rules for percutaneous coronary intervention (PCI) were developed using data
collected before the broader use of new interventional devices.
METHODS Data were collected on 15,331 consecutive hospital admissions by six clinical centers. Logistic
regression analysis was used to predict the risk of in-hospital mortality.
RESULTS Variables associated with an increased risk of in-hospital mortality included older age,
congestive heart failure, peripheral or cerebrovascular disease, increased creatinine levels,
lowered ejection fraction, treatment of cardiogenic shock, treatment of an acute myocardial
infarction, urgent priority, emergent priority, preprocedure insertion of an intraaortic balloon
pump and PCI of a type C lesion. The receiver operating characteristic area for the predicted
probability of death was 0.88, indicating a good ability to discriminate. The rule was well
calibrated, predicting accurately at all levels of risk. Bootstrapping demonstrated that the
estimate was stable and performed well among different patient subsets.
CONCLUSIONS In the current era of interventional cardiology, accurate calculation of the risk of in-hospital
mortality after a percutaneous coronary intervention is feasible and may be useful for patient
counseling and for quality improvement purposes. (J Am Coll Cardiol 1999;34:681–91) ©
1999 by the American College of Cardiology
In the 20 years since its use was first reported by Gruntzig
(1), percutaneous coronary interventions (PCI) have become
a frequently performed therapeutic procedure in patients
with coronary artery disease. It has been estimated that in
1994, over 428,000 coronary angioplasty procedures were
performed in the U.S. (2). In more recent years, balloon
angioplasty has been joined by many nonballoon devices
that have enhanced the technique’s capability, extended its
indications and, in some cases, lowered the rates of adverse
outcome (3). The ultimate benefit of PCI will be judged by
its effect on the relief of angina, its prevention of myocardial
infarction (MI) and its effects on long-term survival (4).
Randomized long-term studies and a recently conducted
meta-analysis suggest that PCI may be the treatment of
choice for some patients with symptomatic coronary artery
disease (5–14). Yet, the anticipated benefits of PCI must be
balanced against its risks. In PCI, balloon-induced baro-
trauma damages the endothelium and often the media and
adventitia of the coronary artery (15). Dissection of the
arterial wall can be detected in 50% to 80% of patients after
PCI (16). Plaque hemorrhage, platelet deposition or clot
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formation may result in lumen compromise. The major
short-term adverse outcomes associated with PCI are the
need for urgent or emergent coronary artery bypass graft
surgery (CABG), postprocedure MI and in-hospital mor-
tality. Patient counseling, optimal clinical decision making
and quality improvement activities require accurate assess-
ment of these risks.
In a previous study (17), we presented a multivariate
prediction rule for in-hospital mortality after PCI using
regional data from 1990 to 1993. Since then, stents, other
nonballoon devices and the newer antiplatelet agents have
become more widely available and used. We now have
validated outcomes data on consecutive PCI procedures
performed in northern New England from 1994 through
1996. This provides an opportunity to identify patient and
disease factors that are associated with in-hospital mortality
and to develop and validate a multivariate prediction rule in
the modern era of PCI.
METHODS
Data collection. The Northern New England Cardiovas-
cular Disease Study Group is a voluntary research consor-
tium composed of clinicians, research scientists and hospital
administrators at the six regional institutions that are the
sole providers of coronary revascularization in northern New
England and one Massachusetts-based institution. The
intent of the group is to foster continuous improvement in
the quality of care of patients with cardiovascular disease in
northern New England through the pooling of process and
outcome data and the timely feedback of data to clinicians
(18,19). Between January 1, 1994 and December 31, 1996,
data were collected by 52 interventionists on 15,331 con-
secutive hospital admissions for a PCI. The capture rate of
procedures was assessed by comparing forms submitted to
the cardiac catheterization logs at each medical center. The
capture rate was 98.6%. The deaths were validated by
comparing the status at discharge recorded on the data
collection form to that reported on hospital discharge
records supplied by the participating medical centers. The
capture rate for in-hospital mortality is 100%.
Data were collected on the following variables: Demo-
graphic data: patient age, gender, height and weight; Medical
history: previous CABG, PCI or MI, family history of
premature coronary artery disease, congestive heart failure,
hypertension, treated diabetes mellitus, current smoking,
hypercholesterolemia, chronic obstructive pulmonary dis-
ease, peripheral vascular disease, cerebrovascular disease,
renal failure and baseline creatinine; Primary indication for
PCI: asymptomatic coronary artery disease, stable angina,
unstable angina (including new-onset angina, rest angina,
angina of increasing frequency or intensity and angina
lasting $20 min irrespective of medication, excluding an-
gina occurring within two weeks of a MI, postinfarction
angina, postinfarction anatomy, primary therapy for acute
MI and cardiogenic shock [systolic blood pressure
,80 mm Hg requiring treatment with pressors or ino-
tropes]); Priority at PCI: emergent, urgent and nonurgent,
as classified by the cardiologist—emergent: factors dictate
that PCI be performed immediately to avoid unnecessary
morbidity or death; urgent: medical factors require that the
patient stay in the hospital until PCI is performed; nonur-
gent: factors indicate that the patient could be discharged to
return electively for PCI; Therapy before, during and after the
procedure: intravenous heparin, intravenous nitroglycerin,
thrombolytic therapy (e.g., tissue plasminogen activator,
streptokinase, urokinase, anisoylated plasminogen strep-
tokinase activator complex [APSAC]) and insertion of an
intraaortic balloon pump (IABP). Cardiac anatomy and
function: cardiac catheterizations were performed at the
participating or referring institutions using their own stan-
dard methods during the course of regular clinical care. Data
collected included percent stenosis of the left main coronary
artery, number of other diseased (.70% stenosis) native
vessels, dominance, number of bypass grafts (distal anasto-
moses), ejection fraction (EF) and left ventricular end-
diastolic pressure (LVEDP); PCI procedure information:
location of lesions attempted (using the Coronary Artery
Surgery Study map) (20); category of lesion (never before
angioplastied, restenosis of lesion angioplastied on previous
admission, acute reocclusion, second or subsequent attempt
to dilate a lesion); lesion status pre- and postprocedure
stenosis using visual estimates or calipers, whatever the local
standard; lesion type (21) (A 5 discrete, ,10 mm in length,
concentric, readily accessible, ,45° bend, smooth contour,
little or no calcification, not totally occluded, not ostial, no
branch involvement, no thrombus seen; B1 (one of the
following) or B2 ($2 of the following) 5 tubular, 10 to
20 mm in length, eccentric, moderate tortuosity of proximal
segment, 45° to 90° bend, irregular contour, moderate to
heavy calcification, total occlusions ,3 months in duration,
ostial location, bifurcation lesions requiring double guide
wires, some thrombus present; C 5 diffuse, .2 cm in
length, excessive proximal tortuosity, extreme angulation
[.90°], unable to protect major side branches, total occlu-
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
COPD 5 chronic obstructive pulmonary disease
EF 5 ejection fraction
IABP 5 intraaortic balloon pump
LVEDP 5 left ventricular end-diastolic pressure
MI 5 myocardial infarction
OR 5 odds ratio
PCI 5 percutaneous coronary intervention
PTCA 5 percutaneous transluminal coronary
angioplasty
PVD 5 peripheral vascular disease
ROC 5 receiver operating characteristic
x2 LR 5 likelihood ratio chi-square test
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sion .3 months in duration, degenerated vein grafts with
friable lesions]); collateral vessels (A 5 feeding distal target
vessel beyond stenosis; B 5 arising from target vessel
beyond stenosis; C 5 no collateral vessels); dissection (flow
limiting, spiral dissection of $2 vessel diameters); device
(balloon, atherectomy, translumen extraction, Rotoblator,
laser, stent); Outcome: in-hospital mortality. The number of
patients in the data set and their status at hospital discharge
were verified using cardiac catheterization laboratory logs
and hospital discharge data. Full definitions for all variables
and the data collection forms can be obtained at http://
www.healthimprov.org/data_forms.htm.
Statistical methods. Standard statistical methods were
used for the calculation of the odds ratios (OR) with 95%
confidence intervals (CI) and p values (22). Logistic regres-
sion analysis was performed with Stata (23,24) to assess the
relation between patient, disease and treatment characteris-
tics and in-hospital mortality. Among the data elements
collected, only EF and creatinine level were missing for a
substantial number of patients. Ejection fraction was not
available for 49.4% of patients. Missing values were im-
puted, from age, gender, acuity (emergency, urgent, nonur-
gent) and previous revascularization, using standard statis-
tical methods (25). Creatinine data were missing for 22.7%
of patients, and missing values were coded as ,2.0 mg/dl.
The likelihood ratio chi-square test (x2 LR) was used to
compare nested logistic regression models (26).
The area under the receiver operating characteristic
(ROC) curve was used as a measure of model discrimination
(27,28). The statistical model was internally validated using
the technique of bootstrap resampling (29). This technique
is efficient and provides nearly unbiased estimates of the
predictive accuracy of the prediction model (30). We devel-
oped the multivariate model on the entire data set, then, 100
samples of 70% were drawn at random with replacement.
The ROC curve area was calculated for each sample. This
allowed the calculation of the standard deviation of the
mean ROC area, and from this the standard error of the
mean (SD/n0.5) (27). In addition, a series of stratum-
specific estimates of the ROC area were calculated to assess
the discriminatory ability of the prediction model for
specific patient subgroups. Resampling methods (using 100
samples) were used to calculate the standard errors of these
estimates. The calibration of the prediction equation was
assessed by comparing the observed and expected numbers
of deaths by decile of predicted risk. The Hosmer-
Lemeshow goodness-of-fit statistic was calculated (31).
RESULTS
Patient characteristics. During the study period, data were
collected on 15,331 consecutive patients who underwent
PCI. There were 165 in-hospital deaths (1.08%). Most of
the patients (67.8%) undergoing PCIs were men. The mean
age was 61.4 years (Table 1). Cardiac risk factors were
common. Many patients had a previous revascularization
(14.2% CABG, 29% PCI). The most common comorbidity
was diabetes (22%), followed by peripheral vascular disease,
cerebrovascular disease and chronic obstructive pulmonary
disease (COPD). The most frequent indication for the
procedure was unstable angina (73.3%). With regard to
priority of coronary angioplasty, 8.8% of the procedures
were classified as emergent; 55.7% were classified as urgent;
and 35.6% were nonurgent. Multivessel coronary artery
disease was present in 34.5% of patients (Table 2). Few
patients had a depressed EF (9.3% with ,40%) or elevated
LVEDP (14.8% with .22 mm Hg). Before the procedure,
46.3% of patients were treated with intravenous nitroglyc-
erin and 0.4% received an IABP. Multivessel PCI took
place in 7.9% of patients. Of the patients, 17.5% had a PCI
in the proximal left anterior descending coronary artery and
5.7% had a graft angioplasty. Type B2 or C lesions were
attempted in 27% of patients. The rates of stent use by year
were 1.8% in 1994, 15.4% in 1995, and 44.9% in 1996—
with an overall rate of 21.7%. The in-hospital mortality
rates by year were 1.2% in 1994, 1.1% in 1995 and 1.0% in
1996. Treatment with IIb/IIIa platelet inhibitors (0.63%),
directional coronary atherectomy (6.6%) and Rotablator
(3.8%) was infrequent.
Risk factors for in-hospital mortality. Univariate assess-
ment of the associations between patient demographic
variables, past medical history, patient status and the risk of
dying was conducted by calculating ORs and p values (Table
1). Older age was significantly (p trend ,0.001) and
positively associated with the risk of a fatal adverse outcome.
Female gender was significantly associated with a fatal (p ,
0.019) adverse outcome. The in-hospital mortality rate for
men was 0.96%, whereas that for women was 1.38%.
Previous CABG (p , 0.001) was associated with increased
risk of in-hospital mortality, but this was not true for a
previous PCI. Diabetes (p 5 0.007), chronic obstructive
pulmonary disease (p , 0.001), peripheral vascular disease
(p , 0.001), cerebrovascular disease (p , 0.001) and body
surface area (p trend ,0.001) were all associated with an
increased risk of a postprocedure death. A creatinine level
$2 mg/dl (OR 6.37, p , 0.001) and a history of congestive
heart failure (OR 8.63, p , 0.001) were associated with an
especially high risk for in-hospital mortality. One surprising
finding in these univariate analyses was that treated hyper-
cholesterolemia was associated with a decreased risk of
in-hospital mortality. This unintuitive association may
identify patients who are under greater medical surveillance,
or it may be a random association. More severe indications
for PCI and increased priority of the procedure were also
strongly associated (p trend ,0.001) with the risk of
in-hospital mortality. As expected, those patients requiring
an emergency procedure or being treated for an acute MI or
cardiogenic shock had the highest rates of death. Although
they are treatment variables, the preprocedure use of throm-
bolytic agents, intravenous nitroglycerin and an IABP may
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Death (%) Odds Ratio
Confidence
Interval (95%) p Value
Age (yr)
,50 18.4 0.46 1.00 Ref.
50–59 24.9 0.53 1.14 0.56–2.29 0.719
60–69 28.9 0.89 1.92 1.02–3.61 0.042
70–79 22.1 2.11 4.62 2.56–8.34 , 0.001
$80 5.7 2.85 6.32 3.22–12.40 , 0.001
p trend , 0.001
Gender
Male 67.8 0.96 1.00 Ref.
Female 32.2 1.38 1.45 1.06–1.98 0.019
Previous CABG
No 85.8 0.97 1.00 Ref.
Yes 14.2 1.93 2.00 1.41–2.85 , 0.001
Previous PCI
No 71.0 1.18 1.00 Ref.
1 24.2 0.94 0.80 0.55–1.16 0.242
$2 4.8 0.95 0.81 0.38–1.74 0.589
p trend 0.250
Previous MI
No 74.5 1.09 1.00 Ref.
Yes 25.5 1.18 1.09 0.77–1.55 0.636
Hypertension
No 47.5 1.08 1.00 Ref.
Yes 52.5 1.13 1.04 0.77–1.41 0.783
Diabetes
No 78.0 0.99 1.00 Ref.
Yes 22.0 1.54 1.57 1.13–2.19 0.007
Current smoker
No 68.0 1.06 1.00 Ref.
Yes 32.0 0.96 0.91 0.64–1.29 0.590
Hypercholesterolemia
No 44.7 1.49 1.00 Ref.
Yes 55.3 0.80 0.53 0.39–0.73 , 0.001
COPD
No 91.3 1.02 1.00 Ref.
Yes 8.7 2.02 2.00 1.32–3.03 0.001
CHF
No 94.7 0.81 1.00 Ref.
Yes 5.3 6.56 8.63 6.19–12.04 , 0.001
PVD
No 90.1 0.90 1.00 Ref.
Yes 9.9 2.97 3.35 2.37–4.74 , 0.001
Previous CVA
No 91.0 0.95 1.00 Ref.
Yes 9.0 2.75 2.96 2.06–4.27 , 0.001
Body surface area (m2)
$2.00 43.1 0.60 1.00 Ref.
1.80–1.99 33.2 0.89 1.49 0.89–2.51 0.129
1.60–1.79 17.6 1.35 2.29 1.32–3.95 0.003
,1.60 6.2 2.14 3.65 1.91–7.01 , 0.001
p trend , 0.001
(continued on next page)
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be important proxies for severity of illness and is informa-
tion available to interventionists before the procedure. All
three were significantly (p , 0.001) associated with an
increased risk of a fatal adverse outcome.
Angiographic and hemodynamic data are summarized in
Table 2. The number of diseased coronary arteries was
associated with the risk of a fatal (p trend ,0.001) adverse
outcome, and those patients with .50% stenosis of the left
main coronary artery were 4.26 (p , 0.001) times as likely
as those without this lesion to die after the procedure. Both
a decreased EF (p trend ,0.001) and an increased LVEDP
(p trend ,0.001) were associated with an increased risk of
in-hospital mortality. The risk of in-hospital mortality was
not significantly associated with a PCI of the proximal left
anterior descending coronary artery (p 5 0.504). A PCI in a
graft was associated with an increased risk of in-hospital
mortality (p , 0.001). Lesion types B1, B2 and C were also
associated with increasing in-hospital death (p trend ,0.001).
Development and validation of the multivariate predic-
tion rule. All variables that were associated (p , 0.05) with
in-hospital mortality in the univariate analyses were in-
cluded in the initial multivariate prediction rule. Variables
not significantly associated with this outcome in the multi-
variate analysis were systematically dropped. The multivar-
iate model predicting in-hospital mortality was statistically
significant (model x2 LR [16 df] 5 466.34, p , 0.0001).
Variables associated with an increased risk of in-hospital
mortality included older age, congestive heart failure, any
vascular disease (peripheral or cerebrovascular), increased
creatinine level, lower EF, treatment of cardiogenic shock or
an MI, urgent or emergency priority, preprocedure insertion
of an IABP and PCI of a type C lesion. The multivariate
model was tested against the “full” model, which contained
all of the significant univariate predictors that had been
dropped (x2 LR [20 df] 5 26.95, p 5 0.1365). The
nonsignificant likelihood ratio chi-squared test indicates
that these variables did not substantially improve the mul-
tivariate prediction model. To examine the ability of the
multivariate model to discriminate the ROC curves of 100,
70% samples of the data (with replacement) were calculated.
The area under the “average” curve was 0.88, with a
standard deviation of 0.019, indicating a good ability to
discriminate between patients who died in the hospital and
those who did not.
The predicted risks of individual patients were rank-
ordered and divided into deciles. Within each decile of
estimated risk, the number of deaths predicted was plotted
against the actual number of observed deaths (Fig. 1). An
identity line (i.e., line of perfect correlation) is shown on the
plot. The Hosmer-Lemeshow goodness-of-fit statistic
across deciles of risk was not statistically significant (x2
[8 df] 5 13.8, p 5 0.087), indicating little departure from
a perfect fit. The variables used in the multivariate predic-
tion rule, their regression coefficients and the p values
associated with each variable are summarized in Table 3. An
example of the calculation of predicted risk for an individual
patient is also described.
To study the performance of the prediction rule on
patient subgroups, the data were stratified according to age
(,70 vs. $70 years), gender, indications for procedure
(stable angina, unstable angina, treatment for MI or cardio-
genic shock), acuity (nonurgent vs. urgent vs. emergent), EF
(,40%; 40–49%, 50–59%, $60%), number of coronary
arteries with a lesion $70% (1, 2 or 3), worst lesion type (A,
B1, B2 or C) and year of procedure. The discriminatory
ability of the prediction equation, as measured by the area
Table 1. Continued
Variable % of Patients
In-Hospital Mortality
Death (%) Odds Ratio
Confidence
Interval (95%) p Value
Creatinine level
Normal 97.8 1.00 1.00 Ref.
$2.00 mg/dL 2.2 6.04 6.37 3.94–10.29 , 0.001
Indications
Stable angina 21.6 0.16 1.00 Ref.
Unstable angina 73.3 0.85 5.46 2.22–13.45 , 0.001
Therapy for MI 4.6 5.50 37.15 14.55–94.89 , 0.001
Shock 0.6 32.18 303.06 113.09–812.2 , 0.001
p trend , 0.001
Priority
Nonurgent 35.6 0.24 1.00 Ref.
Urgent 55.7 0.82 3.46 1.91–6.27 , 0.001
Emergent 8.8 6.35 28.29 15.73–50.87 , 0.001
p trend , 0.001
CABG 5 coronary artery bypass graft surgery; CHF 5 congestive heart failure; COPD 5 chronic obstructive pulmonary
disease; CVA 5 cerebrovascular accident; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention; PVD 5
peripheral vascular disease; Ref 5 reference.
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under the ROC curve, is calculated for each strata (Table 4).
They are remarkably consistent. In 21 of 25 strata, the ROC
areas were $0.80. The equation predicts only slightly less well
for the 4.4% of patients undergoing PCI for the treatment of
an acute MI (ROC area 5 0.77). A lower value was seen
among the 0.6% of patients being treated for cardiogenic shock
(ROC area 5 0.59).
DISCUSSION
In this contemporaneous, prospective cohort study of in-hospital
mortality after PCIs in northern New England in 1994 to 1996,
data were collected from 52 interventional cardiologists on 15,331
consecutive hospital admissions for PCI, representing over 98.5%
of all patients who underwent a PCI during the study period.
These data were used to develop and internally validate a multi-
variate prediction equation for in-hospital mortality that required
only routinely collected data known before the PCI. The discrim-
inatory characteristics of the prediction equation and its calibration
were good. This prediction equation may be useful for patient
counseling and to assess outcomes of PCI.
Choice of variables. In developing this prediction equa-
tion, our choice of variables was guided by face validity and














No. diseased vessels ($70% stenosis)
1 65.5 0.79 1.00 Ref.
2 22.8 1.23 1.57 1.08–2.29 0.017
3 11.7 2.67 3.46 2.41–4.97 , 0.001
p trend , 0.001
LMCA ($50% stenosis)
No 97.2 1.02 1.00 Ref.
Yes 2.8 4.21 4.26 2.59–7.01 , 0.001
Ejection fraction (%)
$60 47.4 0.30 1.00 Ref.
50–59 29.5 0.70 2.35 1.09–5.08 0.029
40–49 13.9 1.95 6.62 3.18–13.77 , 0.001
,40 9.3 5.15 18.18 9.23–35.81 , 0.001
p trend , 0.001
LVEDP (mm Hg)
#14 48.1 0.61 1.00 Ref.
15–18 23.2 1.26 1.79 0.99–3.24 0.052
19–22 13.9 1.05 0.61 0.31–1.21 0.160
.22 14.8 3.86 5.15 3.14–8.43 , 0.001
p trend , 0.001
Intravenous NTG
No 53.7 1.13 1.00 Ref.
Yes 46.3 1.57 1.39 0.96–2.02 0.083
IABP
No 99.6 1.00 1.00 Ref.
Yes 0.4 26.23 34.90 19.30–63.10 , 0.001
Graft
No 94.3 1.00 1.00 Ref.
Yes 5.7 2.97 3.04 1.99–4.65 , 0.001
Lesion type
A 27.1 0.25 1.00 Ref.
B1 45.9 1.11 4.50 2.24–9.02 , 0.001
B2 17.6 1.27 5.18 2.45–10.92 , 0.001
C 9.4 2.86 11.83 5.68–24.62 , 0.001
p trend , 0.001
Proximal LAD
No 82.5 1.08 1.00 Ref.
Yes 17.5 1.23 1.14 0.78–1.67 0.504
IABP 5 intraaortic balloon pump; LAD 5 left anterior descending coronary artery; LMCA 5 left main coronary artery;
LVEDP 5 left ventricular end-diastolic pressure; NTG 5 nitroglycerin; Ref 5 reference.
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by studies done by other investigators. With respect to face
validity, it must be biologically plausible to believe that there
would be an association between the specific patient or
disease characteristic and the outcome of interest. Another
valuable source of insight was obtained from studies done by
other investigators. Our initial approach to data collection
for the Percutaneous Transluminal Coronary Angioplasty
(PTCA) Registry was influenced by the work of Detre et al.
(32). In 1991, we developed our first PTCA mortality
prediction equation (33). We were participants in the
working group of PTCA risk factors convened by Block et
al. (34) and were guided by this experience, and we thought
that it would be worthwhile to update the prediction
equation using contemporaneous data.
Model validation. In the internal validation of the predic-
tion equation, our approach was to use bootstrap resampling
to estimate the standard deviation of the ROC area. This
has been shown to be more efficient than split-sample cross
validation (35). In addition, we looked at strata of patient
groups to see whether the equation discriminates similarly
for each. The prediction equation had good performance
characteristics overall and within groups.
Study limitations. The regional nature of the data reflects
wide experience within this geographic area during a specific
period. However, our data set of 15,331 patients had only
165 deaths (1.08%) and may not be sufficient for an accurate
prediction in some of the smaller patient subgroups. As the
practice of PCI changes, increases in the use of stents and
novel antiplatelet agents and further reductions of in-
hospital mortality may occur, which could change those risk
factors of predictive death. However, in northern New
England, there has been very little change over time in the
risk of in-hospital mortality after PCI (1.01% in 1990–1993
vs. 1.08% in 1994–1996). Furthermore, this report only
considers mortality after PCIs. Mortality rates are required
by the Joint Commission on Accreditation of Healthcare
Organizations (JCAHO) clinical indicator report, are
tracked by hospitals and health care systems and will
certainly be reported in the American College of Cardiology
National Registry. Mortality rates are important but cer-
tainly are not sufficient for the full evaluation of PCI.
Nonfatal adverse outcomes are also important, as are patient
functional status, patient satisfaction and resource use.
Comparisons with other studies. There have been a num-
ber of multivariate analyses of risk factors associated with
in-hospital adverse outcomes after PCI. Three studies used
data from large registries. Using 1992 data from the
Registry of the Society for Cardiac Angiography and Inter-
ventions, Kimmel et al. (36) developed a six-variable pre-
diction rule estimating the risk of major complications
(death, MI, emergent CABG). The variables included
multivessel disease, unstable angina, recent MI, type C
Figure 1. Observed vs. expected mortality by decile of risk.
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lesion or angioplasty of the left main coronary artery, shock,
age and aortic valve disease. The prediction rule showed
good discriminating ability (ROC area 5 0.71) and was
tested on independently collected data (ROC area 5 0.65).
In a series of 5,827 patients undergoing PCI in New York
State in 1991, Hannan et al. (37) analyzed risk factors for
fatal outcomes. In multivariate analyses, they found that
female gender, hemodynamic instability, shock and low EF
predicted in-hospital mortality. The logistic regression
model had good discriminating ability (ROC area 5 0.88);
no validation was reported. Using the 1985–1986 National
Heart, Lung, and Blood Institute’s Coronary Angioplasty
Registry, Kelsey et al. (38) found that female gender, age,
congestive heart failure, diabetes and multivessel disease
were associated with post-PCI in-hospital mortality. This
model was not independently validated.
Other studies have used data from single institutions.
Two of these validated their multivariate models. Empha-
sizing long-term outcome, Mick et al. (39) analyzed data
from 5,000 consecutive patients seen at the Cleveland Clinic
between 1980 and 1988. Patients undergoing PCI for acute
ischemic events were excluded. In multivariate analyses
using Cox proportional hazards modeling, they found that
age .60 years, extent of coronary artery disease, Canadian
Cardiovascular Society functional class, previous PCI, male
gender, history of diabetes mellitus, history of hypertension
and history of congestive heart failure were significant
predictors of event-free survival. This prediction model was
developed on 4,000 patients and validated on 1,000 other
patients. The ROC area for the model showed relatively
good predictive accuracy (ROC 5 0.74). From a 1986–
1989 case series at Duke University (658 patients), Tenaglia
et al. (40) developed a scoring system for predicting abrupt
vessel closure associated with PCI from lesion characteris-
tics. Variables included branch location, length of the lesion,
presence of thrombus and lesions of the right coronary
artery. Bootstrapping was used to provide internal validation
of the multivariate model.
Conclusions. The current study is generally in agreement
with these reports and with our previous prediction rule for
1990–1993 (17). Still included in the multivariate model are
age, procedural priority and indication for and preprocedure
use of an IABP. However, gender, history of MI, use of
preprocedure intravenous nitroglycerin, LVEDP, number
of diseased coronary arteries and an intervention on a
proximal left anterior descending coronary artery are no
longer multivariate predictors of death. Some of these risk
factors are markers for patients who have little cardiac
reserve or will develop a large amount of ischemia with an
acute complication. It is possible that with the availability of
bailout devices like perfusion catheters and stents, some of
Table 3. Prediction of the Risk of In-Hospital Mortality After PCI
Variables (1 5 yes, 0 5 no) Adjusted OR Coefficients Z Score p Value
Age (yr)
50–59 0.93 20.0744 20.193 0.847
60–69 1.63 0.4881 1.418 0.156
70–79 3.32 1.1987 3.634 , 0.001
$80 3.72 1.3147 3.519 , 0.001
Therapy for AMI 1.85 0.6142 2.207 0.027
Cardiogenic shock 6.10 1.8087 4.988 , 0.001
Urgent priority 2.19 0.7853 2.708 0.007
Emergent priority 7.71 2.0424 5.900 , 0.001
EF (%)
50–59 2.53 0.9264 2.684 0.007
40–49 3.32 1.2005 3.265 0.001
,40 5.16 1.6408 4.273 , 0.001
Creatinine level $2.0 2.32 0.8402 2.916 0.004
Any PVD (cerebrovascular or
lower extremity)
2.12 0.7494 3.785 , 0.001
CHF (current or previous admission) 3.01 1.1019 5.448 , 0.001
Preoperative IABP 3.91 1.3634 3.274 0.001
Lesion type C (worst lesion to be
attempted)
1.94 0.6639 3.093 0.002
Intercept 27.6129
Model x2 (16 df) 5 466.34, p , 0.0001. Calculation of predicted risk using patient data and logistic regression coefficients:
Calculate the odds of in-hospital mortality 5 exp(27.6129 2 [0.0744 3 age 50–59] 1 [0.4881 3 age 60–69] 1 [1.1987 3
age 70–79] 1 [1.3147 3 age $80] 1 [0.6142 3 AMI therapy] 1 [1.8087 3 cardiogenic shock] 1 [0.7853 3 urgent] 1
[2.0424 3 emergent] 1 [0.9264 3 EF 50–59] 1 [1.2005 3 EF 40–49] 1 [1.6408 3 EF ,40] 1 [0.8402 3
creatinine $2] 1 [0.7494 3 any PVD] 1 [1.1019 3 any CHF] 1 [1.3634 3 preoperative IABP] 1 [0.6639 3 type C lesion].
Predicted risk of in-hospital mortality 5 odds/(1 1 odds).
AMI 5 acute myocardial infarction; CHF 5 congestive heart failure; EF 5 ejection fraction; IABP 5 intraaortic balloon
pump; OR 5 odds ratio; PVD 5 pulmonary vascular disease.
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these risk factors are no longer so important. New risk
factors in the model include congestive heart failure, pe-
ripheral or cerebrovascular disease, elevated creatinine level,
EF and intervention on a type C lesion. The first three risk
factors were not previously collected, and there has been
improved collection of EF. It is likely that even in the era of
stents, type C lesions are difficult to dilate and do not leave
much room for technical error.
In this contemporary, regional, prospective study, a num-
ber of strong risk factors for in-hospital mortality after PCI
were identified and a multivariate prediction equation was
developed and internally validated. This equation discrim-
inates well across a broad range of patient risk factors. Using
either a programmable calculator or a microcomputer, this
equation is easily solved. We conclude that the calculation
of context-specific estimate of risk using routinely available
preprocedure data is feasible and may be useful for patient
counseling and for quality assurance purposes in the modern
era of interventional cardiology. External validation remains
to be accomplished by using the prediction equation on data
other than that from which it was derived. This constitutes
a more rigorous test of the multivariate prediction model
and should be done both regionally and in other settings.
APPENDIX: NORTHERN NEW ENGLAND
CARDIOVASCULAR DISEASE STUDY GROUP
Writing Committee: Gerald T. O’Connor, PhD, DSc2,
David J. Malenka, MD2, Hebe Quinton, MS2, John F.
Robb, MD2, Mirle A. Kellett, Jr., MD5, Samuel Shubrooks,
MD1, William A. Bradley, MD7, Michael J. Hearne, MD7,
Mathew W. Watkins4, David E. Wennberg, MD6, Bruce
Hettleman, MD2, Daniel J. O’Rourke, MD, MS2, Paul D.
McGrath6, Thomas Ryan, Jr., MD5, Peter VerLee, MD3
Beth Israel–Deaconess Medical Center, Boston, Massa-
chusetts1: David Brackett, RN, Mary Bogosian, RN,
CCP, Christian Campos, MD, Jeannie Fischer, PA, Philip
J. Fitzpatrick, MD, Beth Jennings, Robert Johnson, MD,
Wendy Kowalker, Patricia Lahey, RN, Stephen J. Lahey,
MD, David Leeman, MD, Keith P. Lewis, MD, Stanley
Lewis, MD, Maria Lustenberger, RN, Peter R. Maggs,
MD, Richard Nesto, MD, Brian O’Connor, CCP, Patty
Pawlow, RN, Kathy Peterson, RN, Patricia Rabett, RN,
Samuel Shubrooks, MD, Cheryl Sirois, RN, Terri Stokes,
RN, MS, Susan Sumner, RN, Paul G. Vivino, MD, Albert
Washko, MD, Ronald Weintraub, MD
Dartmouth-Hitchcock Medical Center, Lebanon, New
Hampshire2: Virginia Beggs, ARNP, MS, John D. Birk-
meyer, MD, Nancy J. O. Birkmeyer, PhD, William Burke,
RCVT, Edward Catherwood, MD, MS, Mike Chamber-
lain, RN, Lindsay D’Anna, PA, Lawrence J. Dacey, MD,
MS, Gordon Defoe, CCP, Kenneth Dixon-Vestal, RN,
Thomas Dodds, MD, Mary Fillinger, MD, Bruce Fried-
man, MD, Christine Heins, RN, Bruce Hettleman, MD,
Douglas James, MD, John E. Jayne, MD, Karen A. Jean,
RN, Pamela Jenkins, MD, PhD, Joseph Kasper, ScD, Lori
Key, RN, Terry Kneeland, MPH, Judith Kobe, RN, Eliz-
abeth Maislen, ARNP, David J. Malenka, MD, Charles
A. S. Marrin, MB, BS, Mary Menduni, RN, Nathaniel
Niles, MD, William C. Nugent, MD, Gerald T. O’Connor,
PhD, DSc, Elaine M. Olmstead, Daniel O’Rourke, MD,
Winthrop Piper, MD, Stephen K. Plume, MD, Hebe B.
Quinton, MS, John Robb, MD, Cathy S. Ross, MS, John
Sanders, MD, William Schults, William F. Sullivan, MS,
Jon Wahrenberger, MD, Beth Wolf
Eastern Maine Medical Center, Bangor, Maine3: Robert
Allen, MD, Jim Blum, MS, Deborah Carey-Johnson, RN,














Total 100 0.88 0.82–0.90
Year of procedure
1994 30.2 0.89 0.83–0.93
1995 34.7 0.86 0.79–0.92
1996 35.1 0.89 0.82–0.95
Patient age (yr)
,70 72.2 0.85 0.78–0.92
701 17.8 0.87 0.80–0.92
Gender
Male 67.7 0.90 0.84–0.94
Female 32.3 0.83 0.76–0.89
Indications
Stable angina 24.2 0.90 0.70–0.995
Angina 70.8 0.81 0.74–0.85
Therapy for MI 4.4 0.77 0.64–0.86
Cardiogenic shock 0.6 0.59 0.44–0.75
Acuity
Nonurgent 35.8 0.82 0.62–0.92
Urgent 55.5 0.79 0.73–0.87
Emergent 8.7 0.86 0.80–0.90
Ejection fraction (%)
.60 29.6 0.78 0.62–0.90
50–59 53.8 0.84 0.77–0.89
40–49 11.9 0.84 0.77–0.89
,40 4.7 0.87 0.76–0.93
No. diseased vessels
.70% stenosis
1 65.5 0.87 0.80–0.93
2 22.8 0.87 0.77–0.93
3 11.7 0.85 0.76–0.90
Worst lesion type
A 36.4 0.86 0.79–0.93
B1 40 0.88 0.83–0.96
B2 15.4 0.85 0.74–0.93
C 8.2 0.84 0.76–0.91
CI 5 confidence interval; MI 5 myocardial infarction; ROC 5 receiver operating
characteristic.
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Hernandez, Jr., MD, Joseph J. Hessel, MD, Robert M.
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bideau, RN, Martha Root, RN, Janice Smith, RN, Chris-
topher M. Terrien, Jr., MD, Edward Terrien, MD, Mat-
thew W. Watkins, MD, Jane Wilde, RN, MSN, William
Witmer, MD
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Keller, MD, David Wennberg, MD, MPH
Maine Medical Center, Portland, Maine6: Lawrence Ad-
rian, PA, Warren D. Alpern, MD, Eric Anderson, Richard
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Seth Blank, MD, John Braxton, MD, Carl E. Bredenberg,
MD, Michael Brennan, PA, David Burkey, MD, Cantwell
Clark, MD, Jane Cleaves, RN, Vincent Conti, CEO,
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RN, PhD, Susan Seekins, RN, Paul W. Sweeney, MD,
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